DELFI Diagnostics Announces Availability of New Fragmentome-Based Cancer Treatment Monitoring Assay

Go back to DELFI Diagnostics Announces Availability of New Fragmentome-Based Cancer Treatment Monitoring Assay
(NASDAQ: IMCR) Delayed: 29.39 --0 (-0%)
Previous Close $29.39    52 Week High $ 
Open $29.39    52 Week Low $ 
Day High $29.39    P/E N/A 
Day Low $29.39    EPS $ 
Volume 201